Open AccessOverexpression of microRNA‑203 can downregulate survivin and function as a potential therapeutic target in papillary thyroid cancer
Author(s) -
XinTao Wu,
Lei Dai,
Zhoujing Zhang,
Jueru Zheng,
Jun Zhao
Publication year - 2019
Publication title -
oncology letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.766
H-Index - 54
eISSN - 1792-1082
pISSN - 1792-1074
DOI - 10.3892/ol.2019.11082
Subject(s) - survivin , oncogene , cancer research , microrna , thyroid carcinoma , papillary thyroid cancer , cancer , molecular medicine , thyroid cancer , biomarker , cell cycle , biology , downregulation and upregulation , medicine , thyroid , gene , genetics
Papillary thyroid cancer (PTC) is the most common type of thyroid carcinoma. PTC has a considerably high five-year survival rate; however, the possibility of recurrence is also high. Therefore, there is a requirement to clarify the molecular mechanism of PTC to promote understanding regarding the development of the disease and further improve prognosis. A number of studies have demonstrated that microRNAs (miRNAs or miRs) contribute to the progression of PTC. The present study revealed that the expression level of miR-203 was significantly lower in PTC tissues and cell lines compared with in the normal controls. In addition, inhibition of miR-203 was identified to be associated with an overexpression of survivin, which was observed in PTC samples. miR-203 regulates the expression of Bcl-2 via its downstream regulator survivin. Furthermore, the present study identified that inhibition of miR-203 histone acetylation was associated with high expression levels of miR-203 in PTC tissue samples. In summary, the results indicate that miR-203 functions as a biomarker and may serve as a candidate target for the development of novel therapeutic strategies to treat PTC.